Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

North Immunology to merge with Aethlon Medical

RECENTLY ACQUIREDSep 17, 2026about 2 hours ago

Acquiring Company

North Immunology

Acquired Company

Aethlon Medical

AustinSan DiegoBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareMedicalTherapeutics

Description

North Immunology has agreed to merge with Aethlon Medical, significantly changing ownership dynamics. Aethlon's shareholders will retain a minority stake, while North Immunology's stakeholders will hold the majority. The merger is anticipated to close in the first quarter of 2027, pending necessary approvals. The combined entity will trade under the ticker NRTX.

Company Information

Company

North Immunology

Location

Austin, Texas, United States

About

North Immunology is a privately held biotechnology company developing bispecific antibodies aimed at treating immune and inflammatory diseases. The company is focused on delivering therapies with the potential for best-in-class efficacy, safety, and patient convenience. Their lead product, NOR-101, targets specific inflammatory pathways in conditions such as atopic dermatitis.

Don't miss North Immunology's next move

Get an email the moment North Immunology makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for North Immunology's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Aethlon Medical?

Aethlon Medical was acquired by North Immunology, based in Austin. The deal was reported on September 17, 2026. North Immunology is a privately held biotechnology company developing bispecific antibodies aimed at treating immune and inflammatory diseases. North Immunology is privately held and operates in Biotechnology.

When did North Immunology acquire Aethlon Medical?

North Immunology's acquisition of Aethlon Medical was reported on September 17, 2026. North Immunology has agreed to merge with Aethlon Medical, significantly changing ownership dynamics. Aethlon's shareholders will retain a minority stake, while North Immunology's stakeholders will hold the majority. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Aethlon Medical do?

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. It is publicly traded (AEMD), operating in Biotechnology, and is based in San Diego.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.